Latest research on Celecoxib

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.

Latest findings

The selective COX-2 inhibitor, Celecoxib, inhibited the growth and metastasis of ectopically implanted Lewis lung and HT29 colon tumours (Masferrer ). [source, 2002]
It has also reported that apoptotic effect of Celecoxib, a selective COX-2 inhibitor, is partly mediated by blocking the activation of the anti-apoptotic kinase AKT (Hsu ). [source, 2002]
For example, Celecoxib, a selective COX-2 inhibitor, induced apoptosis of a prostate cancer cell line through a target other than COX-2 (Hsu ). [source, 2002]
Several compounds such as difluoromethylornithine (an inhibitor of polyamine synthesis) and perillyl alcohol (a monoterpene) are already in phase I-II prevention testing, and trials for others such as Celecoxib, a COX-2 inhibitor, and ZD1839, a TYROSINE kinase inhibitor, are in the active planning stage [32,33,34,35]. [source, 2001]
This hypothesis led to an intensive worldwide search for selective COX-2 inhibitors; since 1999 rofecoxib (Vioxx®) and Celecoxib (Celebrex®) have been available on the markets. [source, 2000]
Recently the US FDA approved Celecoxib for the treatment of the potentially life-threatening and rare genetic disorder called familial adenomatous polyposis. [source, 2000]
The use of COX-2-selective drugs such as rofecoxib and Celecoxib also seems to be a safer option than using other NSAIDs in these risk groups. [source, 2000]
Celecoxib has been shown to inhibit uPA. [source, 1999]
Captopril dramatically increases renin formation and plasma renin levels and Celecoxib reduces this effect. [source, 1999]
However if a classical NSAID or the Cox-2 selective Celecoxib were administered concomitantly with the antigen, an inflammatory reaction resulting in villous atrophy and crypt proliferation was elicited. [source, 1999]